The prevalence, patients' characteristics, and hyper-Lp(a)-emia risk factors in the Polish population. The first results from the PMMHRI-Lp(a) Registry
Progress in Cardiovascular Diseases · 2024
DOI: 10.1016/j.pcad.2024.08.004 ↗Kurz gefasst
Fachartikel in der Zeitschrift Progress in Cardiovascular Diseases, 2024. Verfasst von Bożena Sosnowska und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Preventive Cardiology and Lipidology, Medical University of Lodz (MUL), Lodz, Poland. Hauptthemen laut MEDLINE: Registries, Lipoprotein(a), Biomarkers. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
BACKGROUND: The knowledge on the prevalence of elevated lipoprotein(a) (Lp(a)), patients' characteristics, and nongenetic risk factors is scarce in some regions including Poland, the largest Central and Eastern European country. Thus, we aimed to present the results from the Lp(a) registry established in Poland's 2nd largest, supra-regional hospital - the Polish Mother's Memorial Hospital Research Institute (PMMHRI). METHODS: The PMMHRI-Lp(a)-Registry was established in January 2022. Since that time all consecutive patients of the Departments of Cardiology, Endocrinology, and outpatient cardiology, diabetology and metabolic clinics have been included. The indications for Lp(a) measurement in the registry are based on the 2021 Polish Lipid Guidelines and new Polish recommendations on the management of elevated Lp(a) (2024). Lp(a) was determined using Sentinel's Lp(a) Ultra, an Immunoturbidimetric quantitative test (Sentinel, Milan, Italy), and the results are presented in mg/dL. RESULTS: 511 patients were included in the registry between Jan 2022 and 15th May 2024. The mean age of patients was 48.21 years. Female patients represented 53.42 % of the population. Elevated Lp(a) levels above 30 and 50 mg/dL were detected in 142 (27.79 %), and 101 (19.8 %) patients, respectively. The mean Lp(a) level was 30.45 ± 42.50 mg/dL, with no significant sex differences [mean for men: 28.80 mg/dL; women: 31.89 mg/dL]. There were also no significant differences between those with and without: coronary artery disease (CAD), dyslipidemia, stroke, heart failure, cancer, diabetes, chronic kidney disease, and thyroid disease. The significant Lp(a) level difference was observed in those with a history of myocardial infarction (MI) vs those without (51.47 ± 55.16 vs 28.09 ± 37.51 mg/dL, p 30 mg/dL, the only hyper-Lp(a)-emia prevalence differences were seen for FH diagnosis (12.88 vs 21.43; p = 0.017), MI prevalence (6.52 vs 16.90 %; p 50 mg/dL (125 nmol/L) except for no statistical difference for thyroid disease. CONCLUSIONS: These results strongly emphasize that Lp(a) should be measured commonly, as its high level is highly prevalent (even every 3rd patient) in patients at cardiovascular disease (CVD) risk in primary and secondary prevention, requiring risk re-stratification and optimization of the treatment. This is especially important in the regions that characterize baseline high CVD risk, which refers to most CEE countries, including Poland.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Preventive Cardiology and Lipidology, Medical University of Lodz (MUL), Lodz, Poland.
- Department of Preventive Cardiology and Lipidology, Medical University of Lodz (MUL), Lodz, Poland; Department of Cardiology and Adult Congenital Heart Diseases, Polish Mother's Memorial Hospital Research Institute (PMM…
- Department of Preventive Cardiology and Lipidology, Medical University of Lodz (MUL), Lodz, Poland; Department of Endocrinology and Metabolic Diseases, Polish Mother's Memorial Hospital Research Institute, Lodz, Poland.
- Department of Endocrinology and Metabolic Diseases, Polish Mother's Memorial Hospital Research Institute, Lodz, Poland.
- Department of Endocrinology and Metabolic Diseases, Medical University of Lodz, 90-419 Lodz, Poland.
Zitieren
APA
Sosnowska, B., Lewek, J., Adach, W., Mierczak, K., Bielecka-Dąbrowa, A., Szosland, K., Zygmunt, A., Dąbrowski, J., & Banach, M. (2024). The prevalence, patients' characteristics, and hyper-Lp(a)-emia risk factors in the Polish population. The first results from the PMMHRI-Lp(a) Registry. Progress in Cardiovascular Diseases. https://doi.org/10.1016/j.pcad.2024.08.004
Vancouver
Sosnowska B, Lewek J, Adach W, Mierczak K, Bielecka-Dąbrowa A, Szosland K, et al. The prevalence, patients' characteristics, and hyper-Lp(a)-emia risk factors in the Polish population. The first results from the PMMHRI-Lp(a) Registry. Progress in Cardiovascular Diseases. 2024. doi:10.1016/j.pcad.2024.08.004
BibTeX
@article{Sosnowska2024,
author = {Sosnowska, Bożena and Lewek, Joanna and Adach, Weronika and Mierczak, Karina and Bielecka-Dąbrowa, Agata and Szosland, Konrad and Zygmunt, Arkadiusz and Dąbrowski, Jan and Banach, Maciej},
title = {The prevalence, patients' characteristics, and hyper-Lp(a)-emia risk factors in the Polish population. The first results from the PMMHRI-Lp(a) Registry},
journal = {Progress in Cardiovascular Diseases},
year = {2024},
doi = {10.1016/j.pcad.2024.08.004}
}
EUVIMED